Publications by authors named "Jacqueline Greer"

Claim this Profile
P
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Renu Singh, Shailly Mehrotra, Mathangi Gopalakrishnan, Ivana Gojo, Judith E Karp, Jacqueline M Greer

Cancer Chemother Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.
Tao Liu, Vijay Ivaturi, Philip Sabato, Jogarao V S Gobburu, Jacqueline M Greer

Clin Transl Sci· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies.
Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jiuping Ji, Jacqueline M Greer

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies.
Shailly Mehrotra, Mathangi Gopalakrishnan, Jogarao Gobburu, Jacqueline M Greer, Richard Piekarz

Br J Clin Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M Greer, L Austin Doyle

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Joshua F Zeidner, Judith E Karp, Amanda L Blackford, B Douglas Smith, Ivana Gojo, Jacqueline M Greer

Haematologica· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Judith E Karp, Brian M Thomas, Jacqueline M Greer, Christopher Sorge, Steven D Gore

Clin Cancer Res· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Judith E Karp, Elizabeth Garrett-Mayer, Elihu H Estey, Michelle A Rudek, B Douglas Smith, Jacqueline M Greer

Haematologica· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Amer M Zeidan, Rebecca M Ricklis, Hetty E Carraway, Hyun D Yun, Jacqueline M Greer

Br J Haematol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia.
Michael W Evans, Anthony D Sung, Ivana Gojo, Michael Tidwell, Jacqueline Greer

Leuk Lymphoma· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Judith E Karp, Tatiana I Vener, Mitch Raponi, Ellen K Ritchie, B Douglas Smith, Jacqueline M Greer

Blood· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Scott H Kaufmann, Judith E Karp, Mark R Litzow, Ruben A Mesa, William Hogan, Jacqueline Greer

Haematologica· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Judith E Karp, B Douglas Smith, Linda S Resar, Jacqueline M Greer, Amanda Blackford

Blood· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Judith E Karp, Amanda Blackford, B Douglas Smith, Katrina Alino, Amy Hatfield Seung, Jacqueline M Greer

Leuk Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Judith E Karp, Karen Flatten, Eric J Feldman, Jacqueline M Greer, David A Loegering

Blood· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Judith E Karp, B Douglas Smith, Ivana Gojo, Jeffrey E Lancet, Jacqueline Greer

Clin Cancer Res· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Judith E Karp, Francis J Giles, Ivana Gojo, Lawrence Morris, Jacqueline Greer

Leuk Res· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies.
Ivana Gojo, Michael L Tidwell, Jacqueline Greer, Naoko Takebe, Karen Seiter

Leuk Res· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.
Judith E Karp, Rebecca M Ricklis, Kumudha Balakrishnan, Janet Briel, Jacqueline Greer

Blood· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Judith E Karp, B Douglas Smith, Mark J Levis, Steven D Gore, Jacqueline Greer

Clin Cancer Res· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
Ivana Gojo, Anchalee Jiemjit, Jane B Trepel, Alex Sparreboom, William D Figg, Jacqueline Greer

Blood· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.
Jeffrey E Lancet, Ivana Gojo, Jason Gotlib, Eric J Feldman, Jacqueline Greer

Blood· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Judith E Karp, Antonino Passaniti, Ivana Gojo, Scott Kaufmann, Keith Bible, Jacqueline Greer

Clin Cancer Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1-beta-d-arabinofuranosylcytosine, mitoxantrone, and bevacizumab.
Judith E Karp, Ivana Gojo, Roberto Pili, Christopher D Gocke, Jacqueline Greer

Clin Cancer Res· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Judith E Karp, Douglas D Ross, Weidong Yang, Michael L Tidwell, Yuetong Wei, Jacqueline Greer

Clin Cancer Res· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis